Fifth Third Bancorp grew its holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Free Report) by 34.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,553 shares of the company’s stock after purchasing an additional 2,194 shares during the period. Fifth Third Bancorp’s holdings in Praxis Precision Medicines were worth $2,491,000 as of its most recent SEC filing.
Several other hedge funds have also recently modified their holdings of the business. Integrated Wealth Concepts LLC purchased a new position in Praxis Precision Medicines in the second quarter worth about $38,000. Parallel Advisors LLC grew its stake in shares of Praxis Precision Medicines by 3,000.0% during the 1st quarter. Parallel Advisors LLC now owns 124 shares of the company’s stock valued at $40,000 after purchasing an additional 120 shares during the period. IFP Advisors Inc increased its position in shares of Praxis Precision Medicines by 632.0% during the 3rd quarter. IFP Advisors Inc now owns 183 shares of the company’s stock valued at $53,000 after purchasing an additional 158 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Praxis Precision Medicines by 10.3% during the 2nd quarter. GAMMA Investing LLC now owns 332 shares of the company’s stock valued at $111,000 after purchasing an additional 31 shares during the last quarter. Finally, Provenance Wealth Advisors LLC purchased a new stake in shares of Praxis Precision Medicines during the 3rd quarter valued at about $128,000. Hedge funds and other institutional investors own 67.84% of the company’s stock.
Praxis Precision Medicines Price Performance
NASDAQ PRAX opened at $300.43 on Friday. The stock’s fifty day moving average price is $286.09 and its 200 day moving average price is $314.25. Praxis Precision Medicines, Inc. has a 1 year low of $160.11 and a 1 year high of $392.70. The company has a market cap of $8.40 billion, a price-to-earnings ratio of -23.47 and a beta of 2.85.
Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The company reported ($3.23) EPS for the quarter, beating the consensus estimate of ($3.54) by $0.31. Research analysts expect that Praxis Precision Medicines, Inc. will post -13.72 earnings per share for the current year.
Analysts Set New Price Targets
A number of equities research analysts have commented on the stock. The Goldman Sachs Group restated a “buy” rating and set a $575.00 target price (up from $470.00) on shares of Praxis Precision Medicines in a research note on Friday, August 21st. Needham & Company LLC reissued a “buy” rating and issued a $582.00 price objective on shares of Praxis Precision Medicines in a research note on Thursday, September 24th. UBS Group assumed coverage on shares of Praxis Precision Medicines in a research report on Wednesday, October 14th. They set a “buy” rating and a $706.00 price objective on the stock. Wall Street Zen cut shares of Praxis Precision Medicines from a “hold” rating to a “sell” rating in a research note on Saturday, October 17th. Finally, Robert W. Baird upped their target price on shares of Praxis Precision Medicines from $514.00 to $568.00 and gave the stock an “outperform” rating in a report on Monday, November 16th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $660.50.
Check Out Our Latest Stock Analysis on PRAX
Praxis Precision Medicines Company Profile
Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. The company applies neuroscience and precision-medicine research to conditions involving abnormalities in brain circuits and neuronal activity. Its investigational programs have included small-molecule therapies for disorders such as essential tremor and epilepsy, as well as genetic-medicine approaches for certain rare neurological conditions. These candidates are in development and are not approved treatments.
Featured Articles
- Five stocks we like better than Praxis Precision Medicines
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Want to see what other hedge funds are holding PRAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Free Report).
Receive News & Ratings for Praxis Precision Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Praxis Precision Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
